Full Press Release Details
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that it will participate at the Annual Cantor Global Health Conference, the Morgan Stanley 24th Annual Global Healthcare Conference, and the Bernstein 3rd Annual Healthcare Forum in September.
Details of the company's participation are as follows:
• 2026 Cantor Global Healthcare Conference Details: Viking management will participate in a fireside chat and investor meetings. Conference Dates: September 9-11, 2026 Fireside Chat Date/Time: Friday, September 11 th at 10:20 am 10:50 am ET Location: New York, NY
• Morgan Stanley 24 th Annual Global Healthcare Conference Details: Viking management will participate in a fireside chat and investor meetings. Conference Dates: September 14-16, 2026 Fireside Chat Date/Time: Monday, September 14 th at 3:20 pm – 3:55 pm ET Location: New York, NY Webcast available
• Bernstein 3 rd Annual Healthcare Forum Details: Viking management will participate in a fireside chat and investor meetings. Conference Dates: September 23-24, 2026 Fireside Chat Date/Time: Wednesday, September 23 rd at 10:30 am – 11:10 am ET Location: New York, NY
A live webcast of the Morgan Stanley fireside chat may be accessed via a link on the Viking Therapeutics website in the Investors & Media section under Webcasts. Additionally, a replay of the webcast will be available on the Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biotechnology company advancing a next-generation portfolio of therapies for obesity and metabolic disease. Guided by deep expertise in metabolic biology and rigorous science, Viking is developing innovative treatments to help people achieve meaningful, lasting health improvements by treating obesity first. The company's lead program, VK2735, is a dual glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist in development in both subcutaneous and oral formulations for obesity. VK2735 is currently being evaluated in Phase 3 clinical studies for obesity, along with maintenance dosing strategies designed to support long-term weight management. Viking is also advancing additional obesity programs, including VK3019, an amylin receptor agonist, VK2809, an orally available thyroid hormone receptor beta agonist for metabolic and liver disease, and VK0214 for the rare genetic disorder X-linked adrenoleukodystrophy (X-ALD).
For more information about Viking Therapeutics, please visit www.vikingtherapeutics.com.